Jenner Institute, University of Oxford, Oxford, UK
NATIVE OUTER MEMBRANE VESICLE (NOMV) VACCINE
Prevention of Gonorrhea
The Jenner Institute is developing a novel gonorrhea vaccine to prevent infections from different strains of gonococcal bacteria, including the most powerful multidrug-resistant strains that are spreading globally at an alarming pace. The vaccine consists of blebs, or fluid-filled blisters, from the outer surface of gonococcus, called Native Outer Membrane Vesicles (NOMV). Working alongside the Oxford Vaccine Group. The intent is that the vaccine will induce protective immunity against gonorrhea that will prevent individuals from developing the disease and also interrupt the spread of antibiotic resistance found in gonococcal bacteria. The CARB-X award is supporting optimization work and scale-up, followed by production of the vaccine in the University’s Clinical Biomanufacturing Facility for a first-in-human study. Jenner researchers aim to produce an affordable vaccine for global use. Gonorrhea is a disease affecting an estimated 78 million people world-wide, particularly women in low- and middle-income countries.
Current Development Stage: Lead Optimization
CARB-X Investment: Initial investment of up to $2.0m with potential option payments up to $5.3m
Initial CARB-X Investment Date: January 1, 2021